MagnetisMM-6

This study is being conducted in two parts. Part 1 explored several doses of daratumumab and lenalidomide (standard treatments for multiple myeloma) given alongside the study medicine elranatamab. The results from Part 1 were used to select the doses for the next part of the study. In Part 2, researchers will use the best dose/dosing schedule from Part 1 and compare the safety and effectiveness of Elranatamab combined with Daratumumab and Lenalidomide against the combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone. 

This study is open-label, which means that both researchers and participants will know which groups the participants have been placed in, and which treatments they will receive. Participants may continue to receive treatment as long as they don’t experience unacceptable side effects and their myeloma doesn’t get worse. During the first week of participation in the clinical trial, participants will need to be hospitalized for a minimum of 2 days when they receive their first dose of Elranatamab, and for a minimum of 1 day when they receive their second dose of Elranatamab.